25 results
424B5
ZVRA
Zevra Therapeutics Inc
21 Nov 23
Prospectus supplement for primary offering
7:40pm
agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed
425
ZVRA
Zevra Therapeutics Inc
31 Aug 23
Business combination disclosure
8:03am
of its choice with respect to the advisability of making and executing of this Agreement. In the event of any dispute or controversy regarding authorship … dispute or controversy regarding authorship of this Agreement, the parties shall be conclusively deemed to be the joint authors hereof, and no part
8-K
EX-10.2
ZVRA
Zevra Therapeutics Inc
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
of making and executing of this Agreement. In the event of any dispute or controversy regarding authorship of this Agreement, the parties shall
8-K
EX-10.3
ZVRA
Zevra Therapeutics Inc
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
. In the event of any dispute or controversy regarding authorship of this Agreement, the parties shall be conclusively deemed to be the joint authors
424B5
ZVRA
Zevra Therapeutics Inc
12 Jul 21
Prospectus supplement for primary offering
4:53pm
prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant
424B3
k8b4v21oh qy2tclu
13 May 21
Prospectus supplement
9:11pm
424B3
lfsnj7zyv0nhzpq
11 Mar 21
Prospectus supplement
9:56pm
424B4
xlwo5rhrzqn3cdywfdc4
8 Jan 21
Prospectus supplement with pricing info
9:38pm
424B5
4m759635zu8im1s6pc
18 Feb 20
Prospectus supplement for primary offering
7:38am